Experimental design and efficient parameter estimation in population pharmacokinetics, Journal of Pharmacokinetics and Biopharmaceutics, vol.46, issue.4, pp.347-360, 1990. ,
DOI : 10.1007/BF01062273
Optimum Experimental Design, Oxford statistical science series, 1992. ,
DOI : 10.1007/978-3-642-04898-2_434
Population design in nonlinear mixed effects multiple responses models: extension of PFIM and evaluation by simulation with NONMEM and MONOLIX, p.16, 2007. ,
NONMEM users guides, NONMEM, 1992. ,
Theory of optimal experiments, 1972. ,
Design of experiments with unknown parameters in variance, Applied Stochastic Models in Business and Industry, vol.84, issue.3, pp.207-218, 2002. ,
DOI : 10.1002/asmb.474
OPTIMAL POPULATION DESIGNS FOR PK MODELS WITH SERIAL SAMPLING, Journal of Biopharmaceutical Statistics, vol.13, issue.1, pp.143-163, 2005. ,
DOI : 10.1002/0471725315
The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis, British Journal of Clinical Pharmacology, vol.35, issue.4, pp.369-376, 1998. ,
DOI : 10.1046/j.1365-2125.1998.t01-1-00790.x
Simultaneous population optimal design for pharmacokineticpharmacodynamic experiments, pp.759-785, 2005. ,
Comparison of some practical sampling strategies for population pharmacokinetic studies, Journal of Pharmacokinetics and Biopharmaceutics, vol.19, issue.2, pp.245-263, 1996. ,
DOI : 10.1007/BF02353491
Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy, The Journal of Rheumatology, vol.27, issue.4, pp.841-850, 2000. ,
Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, pp.1020-1038, 2005. ,
DOI : 10.1016/j.csda.2004.07.002
Clinical Pharmacokinetics and Use??of??Infliximab, Clinical Pharmacokinetics, vol.20, issue.1, pp.46645-660, 2007. ,
DOI : 10.2165/00003088-200746080-00002
Finding the observed information matrix when using the EM algorithm, Journal of the Royal Statistical Society. Series B (Methodological), vol.44, issue.2, pp.226-233, 1982. ,
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis and Rheumatism, issue.9, pp.411552-1563, 1998. ,
A maximum likelihood estimation method for random coefficient regression models, Biometrika, vol.73, issue.3, pp.645-656, 1986. ,
DOI : 10.1093/biomet/73.3.645
Optimal design in random-effects regression models, Biometrika, vol.84, issue.2, pp.429-442, 1997. ,
DOI : 10.1093/biomet/84.2.429
Non-Linear Mixed Effects Modeling ??? From Methodology and Software Development to Driving Implementation in Drug Development Science, Journal of Pharmacokinetics and Pharmacodynamics, vol.72, issue.6, pp.161-183, 2005. ,
DOI : 10.1007/s10928-005-0062-y
Approximations to the log-likelihood function in the nonlinear mixed-effects model, Journal of Computational and Graphical Statistics, vol.4, issue.1, pp.12-35, 1995. ,
Design in nonlinear mixed effects models: Optimization using the Fedorov???Wynn algorithm and power of the Wald test for binary covariates, Statistics in Medicine, vol.39, issue.28, pp.265162-5179, 2007. ,
DOI : 10.1002/sim.2910
URL : https://hal.archives-ouvertes.fr/hal-00263513
Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs, Computer Methods and Programs in Biomedicine, vol.65, issue.2, pp.141-151, 2001. ,
DOI : 10.1016/S0169-2607(00)00117-6
Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics, Journal of Biopharmaceutical Statistics, vol.13, issue.2, pp.209-227, 2003. ,
DOI : 10.1081/BIP-100101009
Optimization of Individual and Population Designs Using Splus, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.6, pp.417-443, 2003. ,
DOI : 10.1023/B:JOPA.0000013000.59346.9a
Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics, Statistics in Medicine, vol.26, issue.6, pp.2623-2639, 2002. ,
DOI : 10.1002/sim.1041
Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model, Computational Statistics & Data Analysis, vol.51, issue.3, pp.1562-1574, 2006. ,
DOI : 10.1016/j.csda.2006.05.007
URL : https://hal.archives-ouvertes.fr/inserm-00182360
Modelling of individual pharmacokinetics for computer-aided drug dosage, Computers and Biomedical Research, vol.5, issue.5, pp.411-459, 1972. ,
DOI : 10.1016/0010-4809(72)90051-1
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis and Rheumatism, issue.6, pp.461451-1459, 2002. ,
Relative efficiency of unequal cluster sizes for variance component estimation in cluster randomized and multicentre trials, Statistical Methods in Medical Research, vol.18, issue.4, pp.439-458, 2008. ,
DOI : 10.1177/0962280206079018
Identification of parametric models from experimental data, 1997. ,
Communications and Control Engineering ,
Results in the construction of D-optimum experimental designs, Journal of the Royal Statistical Society B, vol.34, pp.133-147, 1972. ,